

Join us at our Pfizer-sponsored symposium at the 37th Annual Congress of the European Society of Intensive Care Medicine (ESICM)!



MBL-producing Enterobacterales and *S. maltophilia*: what's new in the treatment landscape?

Tuesday, 8 October 2024 | 12:30–13:30 CEST | Room 111
CCIB – Barcelona International Convention Centre, Barcelona, Spain



Dr. Ricard Ferrer



Prof. Stefania Stefani



Prof. Marco Falcone

Our expert faculty, **Dr. Ricard Ferrer** (Vall d'Hebron Hospital, Barcelona, Spain), **Prof. Stefania Stefani** (University of Catania, Italy) and **Prof. Marco Falcone** (University of Pisa, Italy) will explore what's new in the treatment landscape of multidrug-resistant Gram-negative bacterial infections in critically ill high-risk patients. The panel will discuss the importance of rapid identification and diagnosis, highlight the unmet need associated with current treatment options for MBL-producing CRE and *S. maltophilia*, and introduce the potential role of aztreonam/avibactam in managing these infections.

12:30	Welcome and introduction	Chair: Ricard Ferrer, Spain
12:35	MBLs in the ICUs: Prevalence and preparedness	Stefania Stefani, Italy
12:45	A new treatment option for patients with infections caused by CRE, including MBL-producing pathogens*	Marco Falcone, Italy
13:05	MBL-producing pathogens* in critically ill patients: What guides treatment?	Ricard Ferrer, Spain
13:20	Questions & answers and concluding remarks	All, moderated by Ricard Ferrer

We look forward to welcoming you to a promising and highly insightful session
Please register for ESICM 2024 [here](#)[†]

*MBL-producing pathogens such as Enterobacterales and *S. maltophilia*.
[†]Congress registration fees apply.

CRE, carbapenem-resistant Enterobacterales; ICU, intensive care unit; MBL, metallo- β -lactamase; SmPC, summary of product characteristics.

This symposium is initiated, organised and funded by Pfizer Inc.

Ficha técnica de aztreonam/avibactam [aquí](#).

The EU SmPC for aztreonam/avibactam can be accessed [here](#).

This drug is centrally authorised in the EU but not yet marketed in Spain pending pricing and reimbursement approval.

Este medicamento está autorizado por procedimiento centralizado en la Unión Europea, pero aún no está comercializado en España pendiente de la aprobación de precio y reembolso.

©2024 Pfizer Inc. All rights reserved. PP-A1E-GLB-0070; September 2024.

